Compare LSPD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | REPL |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2020 | 2018 |
| Metric | LSPD | REPL |
|---|---|---|
| Price | $10.94 | $11.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 8 |
| Target Price | $10.85 | ★ $19.50 |
| AVG Volume (30 Days) | 805.4K | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.93 | N/A |
| Revenue Next Year | $12.42 | $497.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.83 | $1.50 |
| 52 Week High | $13.72 | $16.33 |
| Indicator | LSPD | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 41.64 |
| Support Level | $10.81 | $6.81 |
| Resistance Level | $11.80 | $12.50 |
| Average True Range (ATR) | 0.36 | 0.68 |
| MACD | 0.10 | -0.14 |
| Stochastic Oscillator | 83.23 | 34.48 |
Lightspeed Commerce Inc is a one-stop commerce platform providing its customers with the critical functionalities needed to engage with consumers, manage their operations, order their inventory, accept payments, and run their business. It has customers globally in over 100 countries, empowering single- and multi-location small and medium-sized businesses to compete in an omni-channel market environment by engaging with consumers across online, mobile, social, and physical channels. Its products are divided into retail, restaurant, and golf categories. Geographically, it operates in Canada, the United States, the United Kingdom, Switzerland, Germany, and Others with the majority of revenue deriving from Canada.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.